The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer
- PMID: 15487449
- DOI: 10.1309/UUQT-E505-PTN5-QJ7M
The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer
Abstract
In this retrospective histologic study, galectin-3 had a sensitivity of 92% (22/24) for papillary thyroid carcinoma and 44% (4/9) for follicular thyroid carcinoma. Thyroid peroxidase (TPO) had a sensitivity of 50% (12/24) for papillary and 11% (1/11) for follicular carcinoma. The combination of galectin-3 and TPO had a sensitivity of 96% (23/24) for papillary and 44% (4/9) for follicular carcinoma. From a prognostic standpoint, of patients whose papillary carcinomas expressed both markers, all became free of disease. Of those whose papillary carcinomas expressed galectin-3 but not TPO, 57% (4/7) became free of disease, 29% (2/7) had persistent disease, and 14% (1/7) had progressive disease. This study confirms previous observations that galectin-3 alone is highly sensitive for papillary carcinoma but not adequately sensitive for follicular carcinoma. TPO alone is not adequately sensitive for the evaluation of any thyroid lesion. The combination of galectin-3 and TPO is complementary as a diagnostic and prognostic tool for patients with papillary carcinoma.
Similar articles
-
Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.Hum Pathol. 2008 Nov;39(11):1656-63. doi: 10.1016/j.humpath.2008.04.006. Epub 2008 Jul 26. Hum Pathol. 2008. PMID: 18657294
-
[Thyroid papillary cancer using TPO staining].Ugeskr Laeger. 2008 Apr 28;170(18):1571. Ugeskr Laeger. 2008. PMID: 18454932 Danish.
-
[CD26/dipeptidyl peptidase IV and thyroid peroxidase as molecular markers for differentiated thyroid carcinoma].Rinsho Byori. 1996 Jan;44(1):42-50. Rinsho Byori. 1996. PMID: 8691639 Japanese.
-
Follicular thyroid lesions, elements that affect both diagnosis and prognosis.J Surg Oncol. 2005 Mar 1;89(3):108-13. doi: 10.1002/jso.20186. J Surg Oncol. 2005. PMID: 15719377 Review.
-
Biomarkers for the diagnosis of thyroid cancer.J Exp Ther Oncol. 2010;8(4):341-52. J Exp Ther Oncol. 2010. PMID: 21222366 Review.
Cited by
-
Follicular variant papillary thyroid carcinoma arising in struma ovarii.Endocr Pathol. 2007 Fall;18(3):182-6. doi: 10.1007/s12022-007-0022-8. Endocr Pathol. 2007. PMID: 18058267
-
Combination of galectin-3, CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer.Oncol Lett. 2017 Oct;14(4):4183-4189. doi: 10.3892/ol.2017.6719. Epub 2017 Aug 4. Oncol Lett. 2017. PMID: 28943926 Free PMC article.
-
Thyroid nodules.Med Clin North Am. 2012 Mar;96(2):329-49. doi: 10.1016/j.mcna.2012.02.002. Med Clin North Am. 2012. PMID: 22443979 Free PMC article. Review.
-
ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy.Ann Surg. 2005 Sep;242(3):353-61; discussion 361-3. doi: 10.1097/01.sla.0000179623.87329.6b. Ann Surg. 2005. PMID: 16135921 Free PMC article.
-
Diagnostic utility of galectin-3 in thyroid cancer.Am J Pathol. 2010 May;176(5):2067-81. doi: 10.2353/ajpath.2010.090353. Epub 2010 Apr 2. Am J Pathol. 2010. PMID: 20363921 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical